The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Frovelan     (6R)-6-methylamino-6,7,8,9- tetrahydro-5H...

Synonyms: Allegro, Auradol, Miguard, Rilamig, Migard, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Frovatriptan


High impact information on Frovatriptan


Chemical compound and disease context of Frovatriptan

  • METHODS: The tolerability and safety of frovatriptan 2.5 mg were assessed during controlled, acute migraine treatment studies, including a study that compared frovatriptan 2.5 mg with sumatriptan 100 mg, as well as a 12-month open-label study during which patients could take up to three doses of frovatriptan 2.5 mg within a 24-hour period [8].
  • Naratriptan and frovatriptan, with their slow onset, high tolerability, and long half-lives, may have a role in aborting prolonged migraine attacks and in headache prevention [9].
  • Frovatriptan may be particularly well suited to patients with migraine of long duration, those prone to recurrence and those troubled by "triptan-type" side effects [10].

Biological context of Frovatriptan


Anatomical context of Frovatriptan


Associations of Frovatriptan with other chemical compounds


Gene context of Frovatriptan

  • Frovatriptan is principally metabolized by the CYP1A2 isoenzyme of cytochrome P-450 and is cleared by the kidney and liver, each having sufficient capacity to compensate for impairment of the other [11].
  • RESULTS: In vitro, frovatriptan was principally metabolized by cytochrome P-450 (CYP) 1A2 but was found not to be an inhibitor or inducer of this or other CYP isoenzymes [15].
  • Vanguard (now Vernalis) has developed frovatriptan, a selective 5-HT1B/1D partial agonist licensed from GlaxoSmithKline as a potential treatment for migraine [188478], [194382], [377863] [18].

Analytical, diagnostic and therapeutic context of Frovatriptan


  1. Frovatriptan for the treatment of cluster headaches. Siow, H.C., Pozo-Rosich, P., Silberstein, S.D. Cephalalgia : an international journal of headache. (2004) [Pubmed]
  2. Frovatriptan for the acute treatment of migraine: a dose-finding study. Goldstein, J., Keywood, C. Headache. (2002) [Pubmed]
  3. Frovatriptan use in migraineurs with or at high risk of coronary artery disease. Elkind, A.H., Satin, L.Z., Nila, A., Keywood, C. Headache. (2004) [Pubmed]
  4. Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. Poolsup, N., Leelasangaluk, V., Jittangtrong, J., Rithlamlert, C., Ratanapantamanee, N., Khanthong, M. Journal of clinical pharmacy and therapeutics. (2005) [Pubmed]
  5. Effects of the novel antimigraine agent, frovatriptan, on coronary and cardiac function in dogs. Parsons, A.A., Valocik, R., Koster, P., Raval, P., Gagnon, R., Tilford, N., Feuerstein, G. J. Cardiovasc. Pharmacol. (1998) [Pubmed]
  6. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Tfelt-Hansen, P., De Vries, P., Saxena, P.R. Drugs (2000) [Pubmed]
  7. Pharmacokinetics of frovatriptan in adolescent migraineurs. Elkind, A.H., Wade, A., Ishkanian, G. Journal of clinical pharmacology. (2004) [Pubmed]
  8. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Géraud, G., Spierings, E.L., Keywood, C. Headache. (2002) [Pubmed]
  9. Comparative aspects of triptans in treating migraine. Adelman, J.U., Lewit, E.J. Clinical cornerstone. (2001) [Pubmed]
  10. Frovatriptan: a review. Goldstein, J. Expert opinion on pharmacotherapy. (2003) [Pubmed]
  11. Clinical pharmacokinetics of frovatriptan. Buchan, P., Keywood, C., Wade, A., Ward, C. Headache. (2002) [Pubmed]
  12. Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan. Comer, M.B. Headache. (2002) [Pubmed]
  13. Clinical efficacy of frovatriptan: placebo-controlled studies. Ryan, R., Géraud, G., Goldstein, J., Cady, R., Keywood, C. Headache. (2002) [Pubmed]
  14. Comparison of the cardiovascular effects of the novel 5-HT(1B/1D) receptor agonist, SB 209509 (VML251), and sumatriptan in dogs. Parsons, A.A., Parker, S.G., Raval, P., Campbell, C.A., Lewis, V.A., Griffiths, R., Hunter, A.J., Hamilton, T.C., King, F.D. J. Cardiovasc. Pharmacol. (1997) [Pubmed]
  15. Frovatriptan: a review of drug-drug interactions. Buchan, P., Wade, A., Ward, C., Oliver, S.D., Stewart, A.J., Freestone, S. Headache. (2002) [Pubmed]
  16. Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries. Parsons, A.A., Raval, P., Smith, S., Tilford, N., King, F.D., Kaumann, A.J., Hunter, J. J. Cardiovasc. Pharmacol. (1998) [Pubmed]
  17. Frovatriptan: a selective type 1B/1D serotonin receptor agonist for the treatment of migraine headache. Cole, P., Rabasseda, X. Drugs of today (Barcelona, Spain : 1998) (2002) [Pubmed]
  18. Frovatriptan Vernalis. Mucke, H.A. Current opinion in investigational drugs (London, England : 2000) (2002) [Pubmed]
  19. Chiral separation of Frovatriptan isomers by HPLC using amylose based chiral stationary phase. Khan, M., Viswanathan, B., Rao, D.S., Reddy, R. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2007) [Pubmed]
WikiGenes - Universities